首页 | 本学科首页   官方微博 | 高级检索  
检索        

补肾通督胶囊对RA患者Th17/Treg平衡影响的研究
引用本文:朱阳春,王英旭,林,琳,侯丽萍.补肾通督胶囊对RA患者Th17/Treg平衡影响的研究[J].世界中医药,2014,9(4):439-442.
作者姓名:朱阳春  王英旭      侯丽萍
作者单位:[1]北京中医药大学,北京100029 [2]太原市类风湿病医院,山西030060
基金项目:基金项目:山西省科技攻关项目(编号:20120313025-8)
摘    要:目的:观察补肾通督胶囊对肾虚寒凝型类风湿性关节炎患者外周血Th17/Treg细胞及血清白细胞介素17A(IL-17A)、转化生长因子-β1(TGF-β1)、IL-10的影响。方法:入选类风湿性关节炎患者随机双盲分为治疗组(36例)和对照组(35例),治疗组口服补肾通督胶囊,对照组口服雷公藤多苷片,均服药12周,采用流式细胞术观察比较治疗前后两组患者外周血Th17/Treg及采用酶联免疫吸附法(ELISA)观察血清IL-17A、TGF-β1、IL-10的变化。结果:治疗后两组与各自治疗前相比,Th17及Th17/Treg显著降低(P0.01),Treg显著升高(P0.01);治疗后两组间比较无统计学意义(P0.05)。治疗后两组与各自组治疗前相比,IL-17A显著降低(P0.01),TGF-β1、IL-10显著升高(P0.01);治疗后两组间比较,治疗组TGF-β1与IL-10升高更加明显(P0.01),IL-17A无统计学意义(P0.05)。结论:补肾通督胶囊可以明显降低肾虚寒凝型类风湿性关节炎患者外周血Th17/Treg水平,降低血清IL-17A含量,而使血清TGF-β1、IL-10含量升高。

关 键 词:补肾通督胶囊  类风湿性关节炎  TGF-β1  IL-10  TGF-β1  IL-10
收稿时间:2013/11/27 0:00:00

Study on Effect of Bushen Tongdu capsule on Peripheral Th17/Treg Ratio of Patients with Rheumatoid Arthritis
Zhu Yangchun,Wang Yingxu,Lin Lin,Hou Liping.Study on Effect of Bushen Tongdu capsule on Peripheral Th17/Treg Ratio of Patients with Rheumatoid Arthritis[J].World Chinese Medicine,2014,9(4):439-442.
Authors:Zhu Yangchun  Wang Yingxu  Lin Lin  Hou Liping
Institution:( Beijing University of Chinese Medicine, Beijing 100029, China ; 2 Taiynan city class rheumatism hospital, Shanxi 030060, China)
Abstract:Objective :To investigate the effect of Bushen Tongdu capsule on peripheral Thl7/Treg ratio and serum IL-17A,TGF-β1 and IL-10 of patients with rheumatoid arthritis(RA). Methods:RA patients were divided randomly and double-blinded into treatment group ( n = 36) that were treated with Bushen Tongdu capsules and control group ( n = 35 ) that were treated with Tripterygium glycosides tab- lets. Patients in both groups were treated for 12 weeks. The changes of peripheral blood Th17/Treg ratio and serum IL-17A,TGF-β1 and IL-IO were observed by flow cytometry and ELISA in patients of both teams before and after the treatments. Results:After treatments, Pe- ripheral Th 17 % , Th17/Treg ratio significantly decreased and Treg% significantly evaluated (P 〈 0. 01 ) in both groups, and there was no statistically significant difference between the two groups after the treatments(P 〉 0. 05). After treatments, the level of serum IL-17A significantly decreased, and TGF-β1 and IL-10 significantly evaluated in both groups( P 〈 0. 01 ). Comparing the two groups, TGF-β1 and IL-IO evaluated more in treatment group (P 〈 0. Ol ), while there was no statistically significant difference between the two groups on the changes of IL-17A( P 〉 0.05 ). Conclusion: Bushen Tongdu capsule can reduce RA patients peripheral Th17/Treg ratio and ser- um IL-17A content, and it also can evaluate serum TGF-β1 and IL-IO content.
Keywords:Th17/Treg  IL-17A  BushenTongdu capsule  Rheumatoid arthritis  Th17/Treg  IL-17A
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《世界中医药》浏览原始摘要信息
点击此处可从《世界中医药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号